Matsuda Susumu, Umemoto Seiji, Yoshimura Koichi, Itoh Shinichi, Murata Tomoaki, Fukai Tohru, Matsuzaki Masunori
Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine.
J Atheroscler Thromb. 2015 Aug 26;22(8):833-44. doi: 10.5551/jat.27292. Epub 2015 Mar 5.
Angiotensin Ⅱ(Ang Ⅱ) produces reactive oxygen species (ROS), thus contributing to the development of cardiac hypertrophy and subsequent heart failure, and stimulates the expression of monocyte chemoattractant protein-1 (MCP-1). In addition, Toll-like receptor 4 (TLR4) is involved in the upregulation of MCP-1. In order to clarify whether TLR4 is involved in the onset of cardiac dysfunction caused by Ang Ⅱ stimulation, we investigated the effects of TLR4 on oxidative stress, the MCP-1 expression and cardiac dysfunction in mice with Ang Ⅱ-induced hypertension.
TLR4-deficient (Tlr4(lps-d)) and wild-type (WT) mice were randomized into groups treated with Ang Ⅱ, norepinephrine (NE) or a subdepressor dose of the Ang Ⅱreceptor blocker irbesartan (IRB) and Ang Ⅱ for two weeks.
Ang Ⅱ and NE similarly increased systolic blood pressure in all drug-treated groups compared to that observed in the control group among both WT and Tlr4(lps-d) mice (p<0.05). In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p<0.05). Furthermore, Ang Ⅱ treatment decreased the left ventricular diastolic function and resulted in a greater left ventricular end-systolic dimension (p<0.05) in addition to producing a five-fold increase in the NADPH oxidase activity, ROS content and MCP-1 expression (p<0.05). In contrast, the Tlr4(lps-d) mice showed little effects of Ang Ⅱ on these indices. In the WT mice, IRB treatment reversed these changes compared to that seen in the mice treated with Ang Ⅱ alone. NE produced little effect on any of the indices in either the WT or Tlr4(lps-d) mice.
TLR4 may be involved in the processes underlying the increased oxidative stress, selectively activated MCP-1 expression and cardiac hypertrophy and dysfunction seen in cases of Ang Ⅱ- induced hypertension.
血管紧张素Ⅱ(AngⅡ)可产生活性氧(ROS),从而促进心肌肥厚及随后的心衰发展,并刺激单核细胞趋化蛋白-1(MCP-1)的表达。此外,Toll样受体4(TLR4)参与MCP-1的上调。为阐明TLR4是否参与AngⅡ刺激所致心脏功能障碍的发生,我们研究了TLR4对AngⅡ诱导高血压小鼠氧化应激、MCP-1表达及心脏功能障碍的影响。
将TLR4基因缺陷(Tlr4(lps-d))小鼠和野生型(WT)小鼠随机分为接受AngⅡ、去甲肾上腺素(NE)或亚降压剂量的AngⅡ受体阻滞剂厄贝沙坦(IRB)与AngⅡ治疗两周的组。
与WT和Tlr4(lps-d)小鼠对照组相比,所有药物治疗组中AngⅡ和NE均同样升高收缩压(p<0.05)。在WT小鼠中,AngⅡ诱导心肌肥厚以及心肌内动脉的血管重塑和血管周围纤维化,并导致心脏单核细胞/巨噬细胞浸润(p<0.05)。此外,AngⅡ治疗降低左心室舒张功能,并导致左心室收缩末期内径增大(p<0.05),同时NADPH氧化酶活性、ROS含量和MCP-1表达增加了五倍(p<0.05)。相比之下,Tlr4(lps-d)小鼠中AngⅡ对这些指标几乎没有影响。在WT小鼠中,与单独接受AngⅡ治疗的小鼠相比,IRB治疗逆转了这些变化。NE对WT或Tlr4(lps-d)小鼠的任何指标几乎都没有影响。
TLR4可能参与了AngⅡ诱导高血压时氧化应激增加、MCP-1表达选择性激活以及心肌肥厚和功能障碍的潜在过程。